A Study to Investigate Canvuparatide Compared With Placebo in Adult Patients With Hypoparathyroidism
160 patients around the world
Available in Argentina, United States
MBX Biosciences
160Patients around the world
This study is for people with
Hypoparathyroidism
Requirements for the patient
From 18 Years
All Gender
Medical requirements
Is an adult ≥18 years of age.
Has a documented diagnosis of post-surgical, chronic HypoPT or genetic, idiopathic, or autoimmune HypoPT for at least 12 months prior to screening.
Intact PTH level below the median value of the normal range.
Minimum requirement for a dose of calcitriol ≥0.5 μg/day, or alfacalcidol ≥1.0 μg/day and (elemental) calcium ≥1000 mg/day for at least 12 weeks prior to screening. In addition, the doses of calcitriol, or alfacalcidol, and calcium should be stable for at least 3 weeks prior to screening.
Two (2) consecutive measurements of albumin-adjusted serum calcium at least 1 week apart within the range of 7.8 to 9.4 mg/dL (1.95 to 2.35 mmol/L).
Has a known history of pseudohypoparathyroidism.
Clinically significant abnormal hematology, clinical chemistry, or coagulation.
Any disease that might affect calcium metabolism or calcium-phosphate homeostasis or PTH levels other than HypoPT, such as active endogenous hyperthyroidism.
Use of therapies affecting the calcium metabolism within 4 weeks prior to randomization.
PTH or PTH-related protein drugs such as PTH(1-84) and PTH(1-34) within 5 weeks prior to screening.